These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8555577)

  • 1. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass.
    Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR
    ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
    Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of a heparin removal device: a valid alternative to protamine.
    Hendrikx M; Leunens V; Vandezande E; Wallyn A; Flameng W
    Int J Artif Organs; 1997 Mar; 20(3):166-74. PubMed ID: 9151153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study.
    Zwischenberger JB; Tao W; Deyo DJ; Vertrees RA; Alpard SK; Shulman G
    Ann Thorac Surg; 2001 Jan; 71(1):270-7. PubMed ID: 11216760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin clearance profiles after systemic anticoagulation using a heparin removal device system.
    Tao W; Callahan JD; Vertrees RA; Brunston RL; Deyo DJ; McRea JC; Zwischenberger JB
    ASAIO J; 1997; 43(6):922-6. PubMed ID: 9386844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow rate dependent ex vivo deheparinization with immobilized cationic ligand.
    Tevaearai HT; Mueller XM; Marty B; Horisberger J; Schapira M; von Segesser LK
    ASAIO J; 1997; 43(5):M487-9. PubMed ID: 9360090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device.
    Tao W; Deyo DJ; Alpard SK; Vertrees RA; Hoang V; Zwischenberger JB
    ASAIO J; 1999; 45(1):50-2. PubMed ID: 9952007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assembly of the Heparin Removal Device for patients with suspected adverse reaction to protamine sulphate.
    Jegger D; Tevaerai HT; Horisberger J; Mueller XM; Seigneuil I; Pierrel N; Boone Y; von Segesser LK
    Perfusion; 2000 Sep; 15(5):453-6. PubMed ID: 11001169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin removal after cardiopulmonary bypass in a patient with adverse reaction to protamine.
    Tevaearai HT; Jegger D; Mueller XM; Horisberger J; von Segesser LK
    Thorac Cardiovasc Surg; 1998 Oct; 46(5):303-4. PubMed ID: 9885123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
    Ovrum E; Holen EA; Tangen G; Brosstad F; Abdelnoor M; Ringdal MA; Oystese R; Istad R
    Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real time measurement of heparin concentration during cardiopulmonary bypass.
    Hashimoto K; Sasaki T; Hachiya T; Takakura H; Onoguchi K; Nagahori R; Takeuchi S
    J Cardiovasc Surg (Torino); 1999 Oct; 40(5):645-51. PubMed ID: 10596996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass.
    Guarracino F; De Cosmo D; Penzo D; Tedesco M; Bossi A; Zussa C; Polesel E; De Stefani R
    Minerva Anestesiol; 2001 Apr; 67(4):165-9. PubMed ID: 11376504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
    von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.